AbbVie to Add Liver Warning on Hep C Drugs | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Coverage Restrictions for Hepatitis C Drugs

Back to News Homepage
Next

Protein Consumption for a Healthy Thanksgiving

AbbVie to Add Liver Warning on Hep C Drugs

The Editors at Hepatitis Central
October 23, 2015

Print this page

The FDA reported that AbbVie’s Hepatitis C drugs have been linked to many cases of serious liver damage.
AbbVie to Add Liver Warning on Hep C Drugs Pin it on Pinterest

FDA warns of deadly liver damage with AbbVie hepatitis drugs

By Matthew Perrone

WASHINGTON (AP) — Federal health officials are warning doctors and patients that two hepatitis C drugs from AbbVie can cause life-threatening liver injury in patients with advanced forms of the disease.

The Food and Drug Administration said Thursday it will require AbbVie to add new warnings to Viekira Pak and Technivie after reported deaths and liver transplants in patients who already had liver damage caused by hepatitis C.

Continue reading this entire article:
http://www.wiscnews.com/lifestyles/health-med-fit/article_995eb62e-41b5-5c19-83b1-f55305e406ff.html

3 Comments
Share
Share
Previous

Coverage Restrictions for Hepatitis C Drugs

Back to News Homepage
Next

Protein Consumption for a Healthy Thanksgiving

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.